Glaukos Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Glaukos (NYSE:GKOS) Full Year 2024 Results

Key Financial Results

• Revenue: US$383.5m (up 22% from FY 2023).
• Net loss: US$146.4m (loss widened by 8.7% from FY 2023).
• US$2.78 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Glaukos Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 7.3%.

In the last 12 months, the only revenue segment was Development and Commercialization of Ophthalmic Therapies contributing US$383.5m. The largest operating expense was General & Administrative costs, amounting to US$261.2m (60% of total expenses). Explore how GKOS's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 19% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Glaukos' balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.